Amphilix is attending BIO-Europe's 30 year anniversary. Join us in Stockholm, Sweden, November 4–6, 2024. Register here: https://bit.ly/4biIK0G
Info
Amphilix AG is a Basel, Switzerland based biotech making bifunctional molecules to treat complex diseases using a proprietary linker platform. The linkers employ sophisticated 3D elements which allows the optimization of physicochemical and pharmacokinetic properties. Our lead project is a new First-in-Class targeted radioligand therapy for cancer for which we have teamed up with the Center of Radiopharmaceutical Sciences at the Swiss Federal Institute of Technology (ETH Zürich). Amphilix' drug target is highly expressed in cancer cells and in tumor-associated growing blood vessels and we have demonstrated selective uptake of our radioligand AMX-0053 within a mouse tumor model. The choice of target and use of the proprietary linker platform to optimize the radioligands fully differentiates Amphilix' product from those of other companies.
- Branche
- Biotechnologie
- Größe
- 2–10 Beschäftigte
- Hauptsitz
- Bettingen
- Art
- Privatunternehmen
- Gegründet
- 2020
- Spezialgebiete
- Drug Discovery, Drug Development, Small molecule chimera, Oncology, Inflammation und Radioligand therapy
Orte
-
Primär
Girenhaldenweg 6
Bettingen, 4126, CH
Beschäftigte von Amphilix AG
Updates
-
Amphiliix had the privilege to be part of this amazing week! https://lnkd.in/dD7hC8DQ
This week, four Swiss #biotech startups joined us in Boston for a three-day program on their way to the BIO International Convention in San Diego next week. Meet the startups and find out more about their experience in Boston as part of the Innosuisse Internationalization Camps! 🚀 The startups are: Nagi Bioscience, whose SydLab System is a benchtop laboratory device allowing standardized drug and chemical testing on microorganisms within disposable microfluidic cartridges. mimiX Biotherapeutics which has developed FastSkin, a dermal substitute developed by mimiX using their Sound Induced Morphogenesis technology, offers a novel solution to help patients struggling to heal from complex wounds. Cellestia Biotech is a fully integrated R&D company specialized in innovative therapeutics with new modes of action to treat autoimmune diseases and multidrug resistant cancers. Amphilix AG is developing small molecular chimeras utilizing a unique linker platform that enables fine-tuning of molecular properties, raising the bar for standard-of-care treatment and addressing unmet medical needs. Here’s what they’ve been up to this week: ⚖️ In a session on incorporation with Laura Stoffel (Gunderson Dettmer) they discussed types of legal structures in the US and their implications. 👨💻 With Alexander Harrall (TriNet) they learned how to hire in the US and discover cultural differences in the recruitment process to attract the best talent. 📃 James Ravitz (McDermott Will & Emery) shared insights on the FDA’s regulatory approval process and got them ready for expansion. 🧪 With Alberto Nobili, the startups got the chance to tour Bayer Co.Lab, an incubator for early-stage healthcare startups. 👥 In a feedback session with investors Doug Zingale and Edward Melia the startups got invaluable advice on their pitches and practiced how to adjust them to the local audience. 🗃️ In a session on taxation with Gerhard Friedrich Schneiders (Rödl & Partner USA) they discussed differences between Switzerland and the US, and the tax implications of different legal entities. 📣 Finally, with Mehdi Aghdaee, MD, PhD (#QuantLifeSciences), they worked on their storytelling skills, practicing how to create a storyline and capture an audience - which will come in handy next week! We welcomed the startups to the US with our Biotech Garden Party, where they were able to meet and network with members of Boston’s biotech community, including representatives from Novartis, Sanofi, Pfizer, and many others who will be attending #BIO2024. Thanks to all who attended the event, and especially to Innosuisse, Greater Zurich Area, Greater Geneva Bern area (GGBa), and Switzerland Global Enterprise for their partnership. Thank you as well to all the experts who shared their time and knowledge with the startups throughout the week! 🙏🏼 Next stop, San Diego! 🌴 #SwissBiotech #SwissStartups
-
+7
-
Amphilix is supported by Innosuisse to participate Bio International in San Diego next week https://lnkd.in/dJZmggdf
Swiss life science startups headed for San Diego
startupticker.ch
-
We’ve just updated our Page. Visit our Page to see the latest updates.
Amphilix AG | LinkedIn
ch.linkedin.com
-
We are looking forward to seeing you in San Diego
Learn More
share.bio.org
-
Amphilix is pleased to attend BioInternational https://lnkd.in/g3xKeUKS
Registration is now open for BIO 2024. Discover inspiration, insights, and exciting partnerships with biotech leaders from around the world.
Register Now
convention.bio.org
-
Another interesting deal in the targeted radiotherapeutic space: AstraZeneca to acquire Fusion to accelerate the development of next-generation radioconjugates to treat cancer https://lnkd.in/dvzmsvkJ
AstraZeneca to acquire Fusion to accelerate the development of next-generation radioconjugates to treat cancer
astrazeneca.com
-
Amphilix will be presenting at Swiss Biotech Day 2024 #swissbiotechday
-
Amphilix is honored to be selected for the Market Validation Camp of Swissnex in Boston 2024
Yesterday, we had the pleasure of meeting up in Bern with startups taking part in the Innosuisse Internationalization Camps in Boston, New York, and San Francisco, as well as recent alumni of the program. It was wonderful to bring all these entrepreneurs together in one place to discuss their experiences and share insights on their internationalization journeys! #SwissStartups Amphilix AG Aseptuva BeeHelpful SA Cellestia Biotech 2150 Datavault Builder AG Egonym Happy Numbers, Inc. Klepsydra Technologies Magnes AG PeriVisionPhenomX Health ShareP - Sustainable Parking Management Smeetz SURI BioTech SurgeonsLab AG ZuriMED Technologies AG Swissnex in San Francisco Swissnex